ORPHAN SYNERGY EUROPE-PHARMA (EPA:OSE) | WebDisclosure

Basculer en Français

11084	Companies
243295	Keywords
171462	Articles
131019	Press releases

Headlines Articles Press releases ORPHAN SYNERGY EUROPE-PHARMA

Home
Companies
ORPHAN SYNERGY EUROPE-PHARMA

PRESS RELEASE

published on 05/22/2026 at 07:30, 4 months 4 days ago

OSE Immunotherapeutics Reports Positive Topline Results of TEDOVA Phase 2 Trial with Tedopi® in Recurrent Ovarian Cancer
OSE Immunotherapeutics announces positive topline results from TEDOVA Phase 2 trial with Tedopi® in recurrent ovarian cancer, presenting at ASCO 2026. Combination with pembrolizumab improves progression-free survival

OSE Immunotherapeutics Tedopi TEDOVA Phase 2 ASCO 2026 Recurrent Ovarian Cancer
BRIEF

published on 04/30/2026 at 07:35, 4 months 26 days ago

OSE Immunotherapeutics Reveals 2025 Financial Results and 2026 Cash Position

Financial Results Cash Position Strategic Roadmap Operating Loss OSE Immunotherapeutics
BRIEF

published on 04/30/2026 at 07:35, 4 months 26 days ago

OSE Immunotherapeutics: 2025 Financial Review and 2026 Outlook

Strategic Partnerships OSE Immunotherapeutics 2025 Financial Results Tedopi® Cash Flow 2026
BRIEF

published on 04/30/2026 at 07:35, 4 months 26 days ago

OSE Immunotherapeutics : Bilan financier de 2025 et perspectives 2026

Partenariats Stratégiques OSE Immunotherapeutics Résultats Financiers 2025 Tedopi® Trésorerie 2026
BRIEF

published on 04/30/2026 at 07:35, 4 months 26 days ago

OSE Immunotherapeutics dévoile ses résultats financiers pour 2025 et sa trésorerie pour 2026.

Résultats Financiers Perte D'exploitation Feuille De Route Stratégique Position De Trésorerie Immunothérapies OSE
PRESS RELEASE

published on 04/30/2026 at 07:30, 4 months 26 days ago

OSE Immunotherapeutics Reports Full Year 2025 Unaudited Consolidated Financial Results and 2026 Q1 Cash Position
OSE Immunotherapeutics reports unaudited full year 2025 financial results and Q1 2026 cash position. Cash runway unchanged till early Q4 2026. Filing of 2025 Registration Document postponed to May 28, 2026

Financial Results Cash Position Registration Document OSE Immunotherapeutics Cash Runway
PRESS RELEASE

published on 04/30/2026 at 07:30, 4 months 26 days ago

OSE Immunotherapeutics publie ses résultats financiers consolidés non audités pour l’exercice 2025 et sa situation de trésorerie du 1er trimestre 2026
OSE Immunotherapeutics publie ses résultats financiers consolidés non audités pour l'exercice 2025 et sa situation de trésorerie du 1er trimestre 2026, montrant une trésorerie de 22,7 millions d'euros en 2025 et 17,0 millions d'euros en mars 2026, prévoyant un horizon de trésorerie stable jusqu'au 4ème trimestre 2026

Résultats Financiers Trésorerie Exercice 2025 OSE Immunotherapeutics Horizon
BRIEF

published on 04/27/2026 at 07:35, 4 months 29 days ago

OSE Immunotherapeutics célèbre la désignation de médicament orphelin de la FDA pour le pegrizéprument

Pegrizeprument Veloxis Pharmaceuticals Immunothérapies OSE Médicament Orphelin De La FDA Greffe Cardiaque
BRIEF

published on 04/27/2026 at 07:35, 4 months 29 days ago

OSE Immunotherapeutics Celebrates FDA Orphan Drug Designation for Pegrizeprument

OSE Immunotherapeutics FDA Orphan Drug Pegrizeprument Veloxis Pharmaceuticals Heart Transplant
PRESS RELEASE

published on 04/27/2026 at 07:30, 4 months 29 days ago

OSE Immunotherapeutics Welcomes FDA Orphan Drug Designation Granted to Pegrizeprument (VEL-101) for Prevention of Organ Rejection in Heart Transplant Patients
OSE Immunotherapeutics welcomes FDA Orphan Drug Designation granted to Pegrizeprument (VEL-101) for prevention of organ rejection in heart transplant patients, a novel immunomodulatory treatment developed in partnership with Veloxis Pharmaceuticals

Orphan Drug Designation Transplant Pegrizeprument VEL-101 Organ Rejection

Accesswire

Published on 09/26/2026 at 01:00, 16 hours 57 minutes ago

Guanajuato Silver Renews Base Shelf Prospectus
Published on 09/26/2026 at 01:00, 16 hours 57 minutes ago

Findev Inc. Provides Update on Victoria Park Loan Exposure and Expected Accounting Impairment
Published on 09/25/2026 at 22:15, 19 hours 42 minutes ago

Rocky Shore Gold Closes First Tranche of Non-Brokered Private Placement
Published on 09/25/2026 at 17:30, 1 day ago

Goldcliff Announces Unit and Flow Through "LIFE" Offerings
Published on 09/25/2026 at 15:00, 1 day 2 hours ago

HM Exploration Provides Program Update for the Lewis Pilley's Project

View all ACCESSWIRE

EQS Group

Published on 09/26/2026 at 15:30, 2 hours 27 minutes ago

QUORRA X5 fait ses débuts mondiaux à REHACARE International 2026 en Allemagne
Published on 09/26/2026 at 15:30, 2 hours 27 minutes ago

QUORRA X5 Makes Its Global Debut at REHACARE International 2026 in Germany
Published on 09/26/2026 at 15:15, 2 hours 41 minutes ago

Timur Turlov Elected FIDE President, Becomes First Kazakh to Lead World Chess
Published on 09/26/2026 at 07:45, 10 hours 12 minutes ago

Green SM Begins Pilot Operations In The Netherlands, Further Expanding Its Presence In Europe
Published on 09/26/2026 at 00:01, 17 hours 55 minutes ago

Photon Energy N.V. Sells 7.6 MWp of PV Operational Assets in Slovakia

Les Echos

Published on 09/26/2026 at 07:00, 10 hours 57 minutes ago

Groupe DLSI - Résultat 1er semestre 2026
Published on 09/25/2026 at 18:00, 23 hours 57 minutes ago

COGRA : RAPPORT FINANCIER ANNUEL 2025/26
Published on 09/25/2026 at 18:00, 23 hours 57 minutes ago

COGRA : RAPPORT FINANCIER ANNUEL 2025/26
Published on 09/25/2026 at 17:45, 1 day ago

COGRA : ASSEMBLÉE GÉNÉRALE MIXTE DU 16 OCTOBRE 2026 / MISE À DISPOSITION DU RAPPORT FINANCIER ANNUEL 2025/2026
Published on 09/25/2026 at 17:40, 1 day ago

Availability of the 2026 half-year financial report

View all LES ECHOS COMFI WIRE